Optibrium™ has announced the expansion of its UK headquarters with a move to larger office premises on Cambridge Innovation Park North.

Axol Bioscience Ltd. has announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

The agreement will see the two companies expand current oligonucleotide technologies, develop new oligonucleotide processes and contribute to global manufacturing capacity for oligonucleotide-based medicines for patients.

Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.

Beckman Coulter Life Sciences announces a series of events to celebrate its 75th anniversary. Highlights include the launch of the Allegra V-15R Benchtop Centrifuge, along with the industry’s highest-volume vertical rotor – the VTi 50.1 – and a contest to find the oldest centrifuge produced by the company.

Awakn Life Sciences Corp. announced today the completion of the world's first ketamine treatment study for behavioral addictions.

Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties.

Maxwell™ Preclinical MRI Magnets do not require liquid helium, facilitating siting.

Bruker has announced the launch of a differentiated benchtop FT-NMR solution for forensic narcotics testing, called the Fourier 80 CrimeLab, with a nuclear magnetic resonance NMR Narcotics Profiling module.

Bio-Rad Laboratories, Inc. has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).